Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT ID: NCT01552915
Last Updated: 2021-06-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
464 participants
INTERVENTIONAL
2012-04-17
2014-01-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
NCT01552902
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00877487
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00500149
Effect of Vyvanse on Driving in Young Adults With ADHD
NCT00801229
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00500071
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lisdexamfetamine Dimesylate
Lisdexamfetamine dimesylate
Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
Methylphenidate Hydrochloride
Methylphenidate Hydrochloride
Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
Placebo
Placebo
Daily oral dosing in the AM for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lisdexamfetamine dimesylate
Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
Methylphenidate Hydrochloride
Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
Placebo
Daily oral dosing in the AM for 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must weigh more than 79.5lb.
* The parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of investigational product for the study duration.
* Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements of the protocol.
* Subject has an ADHD-RS-IV total score ≥28.
* Subject is able to swallow a capsule.
* Subject does not have hypertension and has a resting sitting blood pressure less than or equal to 135/85mmHg.
Exclusion Criteria
* Diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
* Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded.
* Subject is underweight or overweight.
* Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition. Mild, stable asthma is not exclusionary.
* Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
* Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.
* Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
* Subject has any clinically significant ECG or clinically significant laboratory abnormality.
* Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
* Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
* Subject has a documented allergy, hypersensitivity, or intolerance to MPH or to any excipients in the reference product.
* Subject has failed to fully respond to an adequate course(s) (dose and duration) of MPH or amphetamine therapy.
* Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine). Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
* Subject has a positive urine drug result.
* Subject has previously participated in this study or another clinical study involving SPD489/NRP104.
* Subject has glaucoma.
* Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
* Subject is female and is pregnant or lactating.
* Subject is well controlled on his/her current ADHD medication.
* Subject has a pre-existing severe gastrointestinal tract narrowing.
13 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Melmed Center
Scottsdale, Arizona, United States
Clinical Study Centers, LLC
Little Rock, Arkansas, United States
Synergy Clinical Research Center
National City, California, United States
Pacific Clinical Research Medical Group
Orange, California, United States
SDS Clinical Trials, Inc.
Orange, California, United States
Peninsula Research Associates, Inc.
Rolling Hills Estates, California, United States
PCSD - Feighner Research
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Neuropsychiatric Research Center of Orange County
Santa Ana, California, United States
Elite Clinical Trials
Wildomar, California, United States
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, United States
Florida Clinical Research Center, LLC
Bradenton, Florida, United States
Sarkis Clinical Trials
Gainesville, Florida, United States
Amedica Research Institute
Hialeah, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Fidelity Clinical Research, Inc.
Lauderhill, Florida, United States
Florida Clinical Research Center, LLC
Maitland, Florida, United States
Scientific Clinical Research, Inc.
Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
Janus Center for Psychiatric Research
West Palm Beach, Florida, United States
Atlanta Institute of Medicine and Research
Atlanta, Georgia, United States
Capstone Clinical Research
Libertyville, Illinois, United States
AMR Baber Research Group, Inc.
Naperville, Illinois, United States
AMR Conventions Research
Naperville, Illinois, United States
American Medical Research, Inc
Oak Brook, Illinois, United States
Advocate Hope Children's Hospital
Oak Lawn, Illinois, United States
Neuroscience Research Institute, Inc
Oak Park, Illinois, United States
Psychiatric Associates
Overland Park, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
Four Rivers Clinical Research
Paducah, Kentucky, United States
Neuroscientific InSights
Rockville, Maryland, United States
Marc Hertzman MD, PC
Rockville, Maryland, United States
Rochester Center for Behavioral Medicine
Rochester Hills, Michigan, United States
Clinical Neurophysiology Services, PC
Sterling Heights, Michigan, United States
Behavioral Medical Center - Troy
Troy, Michigan, United States
Precise Research Centers
Flowood, Mississippi, United States
Comprehensive Psychiatric Associates
Gladstone, Missouri, United States
St Charles Psychiatric Associates
Saint Charles, Missouri, United States
Premier Psychiatric Research Institute
Lincoln, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, United States
Center for Emotional Fitness
Cherry Hill, New Jersey, United States
CRCNJ - Clinical Research Center of New Jersey
Gibbsboro, New Jersey, United States
Neurcognitive Institute
Mount Arlington, New Jersey, United States
Mount Sinai School of Medicine
New York, New York, United States
Duke Child and Family Study Center
Durham, North Carolina, United States
Innovis Health, LLC
Fargo, North Dakota, United States
North Coast Clinical Trials
Beachwood, Ohio, United States
University of Cincinnati Dept. of Psychiatry & Behavioral
Cincinnati, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
The Ohio State University Nisonger Center
Columbus, Ohio, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Professional Psychiatric Services
Mason, Ohio, United States
Family Practice of Wadsworth, Inc.
Wadsworth, Ohio, United States
Cyn3rgy Research
Gresham, Oregon, United States
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
Portland, Oregon, United States
Summit Research Network (Oregon) Inc.
Portland, Oregon, United States
Oregon Center for Clinical Investigations, Inc.
Salem, Oregon, United States
Carolina Clinical Trials, Inc.
Charleston, South Carolina, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States
Research Strategies of Memphis, LLC
Memphis, Tennessee, United States
FutureSearch Trials
Austin, Texas, United States
Claghorn-Lesem Reseach Clinic, Ltd.
Houston, Texas, United States
Texas Center for Drug Development, Inc.
Houston, Texas, United States
Red Oak Psychiatry Associates, PA
Houston, Texas, United States
R/D Clinical Research, Inc.
Lake Jackson, Texas, United States
Westex Clinical Investigations
Lubbock, Texas, United States
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States
University of Texas HSC at San Antonio Dept. of Psychiatry
San Antonio, Texas, United States
Wharton Research Center, Inc.
Wharton, Texas, United States
Psychiatric & Behavioral Solutions
Salt Lake City, Utah, United States
University of Virginia Child and Family Psychiatry Clinical
Charlottesville, Virginia, United States
NeuroScience, Inc.
Herndon, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Eastside Therapeutic Resource
Kirkland, Washington, United States
Summit Research Network (Seattle), LLC
Seattle, Washington, United States
Rockwood Clinic, P.S.
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2017 Nov;31(11):999-1014. doi: 10.1007/s40263-017-0468-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPD489-405
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.